TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis

NCT06726577 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG: TP04HN106
DRUG: Saline

Sponsor

Talengen Institute of Life Sciences, Shenzhen, P.R. China.

Collaborators

[object Object]